BLTE Latest Quarter’s Earnings
Announce Date8/13/2026
EPS Actual (USD)-0.71
Revenue Actual (USD)--
Belite Bio Inc Earnings Dates & Reports
This page offers detailed Belite Bio Inc earnings data including the latest Belite Bio Inc earnings report, the upcoming Belite Bio Inc earnings date, historical data and Belite Bio Inc earnings call news.
BLTE Upcoming Quarter's Earnings
Announce Date--
EPS Forecast (USD)--
Revenue Forecast (USD)--
BLTE FY2025 Earnings
EPS (YoY)-2.31-95.52%
Revenue (YoY)----
Belite Bio Inc (BLTE) Earnings History
| Release Date | Period End | EPS/Forecast | Revenue/Forecast | EPS Surprise % | Revenue Surprise % |
|---|---|---|---|---|---|
| 8/13/2026 | 06/2026 | -0.71/-0.79 | --/0.00 | 10.35% | -- |
| 5/20/2026 | 03/2026 | -0.68/-0.64 | --/0.00 | -6.29% | -- |
| 3/2/2026 | 12/2025 | -1.19/-0.55 | --/0.00 | -117.22% | -- |
| 11/10/2025 | 09/2025 | -0.28/-0.49 | --/0.00 | 41.99% | -- |
| 8/11/2025 | 06/2025 | -0.50/-0.42 | --/0.00 | -19.96% | -- |
| 5/14/2025 | 03/2025 | -0.44/-0.37 | --/0.00 | -19.14% | -- |
| 3/17/2025 | 12/2024 | -0.32/-0.31 | --/0.00 | -4.30% | -- |
| 11/12/2024 | 09/2024 | -0.28/-0.29 | --/0.00 | 1.80% | -- |
Belite Bio Inc Latest Earnings Call Transcripts
Belite Bio (BLTE) Q2 2026 Earnings Call: Tinlarebant FDA Review and $780M Cash
Belite Bio Q2 2026 earnings call: FDA priority review for Tinlarebant, a February 12, 2027 PDUFA date, $780 million in cash and higher expenses.